Teva Pharmaceutical Industries has entered into a settlement agreement related to Nuvigil patent infringement litigation with Mylan.
Under the agreement, Mylan is allowed to sell generic versions of 50mg, 150mg, and 250mg Nuvigil in June 2016, or earlier under certain undisclosed circumstances.
Teva accepts that Mylan was the first generic company to file an abbreviated new drug application for the dosage strengths of Nuvigil and the pending litigation will be dismissed.
Nuvigil (Armodafinil Tablets, 50mg, 150mg, and 250mg) is indicated for excessive sleepiness associated with narcolepsy, shift work disorder or treated obstructive sleep apnea.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/teva-settles-patent-infringement-litigation-with-mylan-010512
